Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastomaKimberley M. Hanssen(The University of Sydney), Michelle Haber(Cancer Institute of New South Wales)Journal of Experimental & Clinical Cancer ResearchAugust 14, 202510.1186/s13046-025-03502-8Cited by 1SaveCiteExport RISWatch citationsRelated PapersDual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma|Clinical Cancer Research|2021|31